This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Ethinyloestradiol is estrogen (hormone). Ethinyloestradiol is used for replacement therapy in women who is deficient of hormone. Ethinyloestradiol is used to treat symptoms associated with menopause and conditions in which hormone levels are low. Ethinyloestradiol is also used to prevent osteoporosis (bone loss).
Indications
Ethinyloestradiol is primarily indicated in conditions like Breast cancer (Off label indication), Dysfunctional uterine bleeding, Gonadal dysgenesis, Hereditary hemorrhagic telangiectasia, Hormone replacement for menopausal symptoms, Hormone replacement therapy, Menopausal symptoms, estrogen deficiency, Osteoporosis prophylaxis, Pre-ovulatory mucus, Prostatic cancer, and can also be given in adjunctive therapy as an alternative drug of choice in Acne, Contraception, Endometriosis, Hirsutism, Menstruation disorders.
Contraindications
Ethinyloestradiol is contraindicated in conditions like Thromboembolism, Genital bleeding, Jaundice, Thrombophlebitis, Cerebrovascular disease, Hepatic carcinoma, Coronary artery disease, Estrogen-dependent cancer, Untreated endometriosis.
Side Effects
The severe or irreversible adverse effects of Ethinyloestradiol, which give rise to further complications include Impotence, Loss of libido, Gynecomastia, Chloasma, MI. Ethinyloestradiol produces potentially life-threatening effects which include Pulmonary embolism, Hypertension, Venous thromboembolism, Endometrial carcinoma, Endometrial hyperplasia, Cerebral thrombosis, Gall bladder disease, Liver tumors, Breast carcinoma, Coronary thrombosis, which are responsible for the discontinuation of Ethinyloestradiol therapy. The signs and symptoms that are produced after the acute over dosage of Ethinyloestradiol include Nausea, Vomiting, Coronary thrombosis, Uterine withdrawal bleeding. The symptomatic adverse reactions produced by Ethinyloestradiol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Vomiting, Weight gain, Fluid retention, Intermenstrual bleeding or spotting, Chloasma, Cholestatic Jaundice, Vaginal candidiasis.
Warnings
High doses of ethinyloestradiol used in treatment of malignant disease should be used with caution in patients with cerebrovascular disorder, coronary artery disease or venous thromboembolism. It should be used with caution in children, because premature closure of epiphysis may occur resulting in inhibited linear growth and small stature.
High Risk Groups
Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
0.4 mg (0.4 (0.4)) 24 hourly PO — 5-7 Days per week for 1-3 Years
Child Dosage
( ) — Not recommended in this age group
Neonatal Dosage
( ) — Not recommended in this age group
Drug Interactions
Ethinyloestradiol is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAmpicillinAprepitantUpon coadministration with aprepitant capsules, the efficacy of hormonal contraceptives during and for 28 days following the last dose of aprepitant capsules may be reduced. Alternative or back-up methods of contraception should be used during treatment with aprepitant capsules and for 1 month following the last dose of aprepitant.Ascorbic AcidChloramphenicolClavulanic AcidCo-AmoxiclavCyproterone (Acetate)GriseofulvinImipramine (HCl)LynoestrenolMeprobamatePhenobarbitonePhenylbutazone Phenytoin (Na)RifampicinSt.Johns Wort ExtractConcurent use may result in irregular menstrual flow.TegaserodTegaserod decreased Ethinyloestradiol plasma concentrations by less than 10% in a clinical study with a low-dose triphasic oral contraceptive (n=45). The mechanism is unknown. There were no changes in ethinyl estradiol concentrations or in contraceptive efficacy. No action is necessary.MinorTetracycline (HCl) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Storage
Tab Store in a well closed container. Protect from Sunlight.